Insmed : Phase 3 Analyses Of Brensocatib In Bronchiectasis Align With Positive Overall Trial Results
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Insmed Inc. (INSM) said it presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fib
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2026302367-12fef6ae83cf4d52ba8036bc7ba65d99.jpg "How to Calculate Sales Tax")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2161540199-d06be0d9f1e54b8bb35b1afc19ad6560.jpg "Where Do Pension Funds Typically Invest?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-481000237-f5f2346d368a455594d212e6e80e30e2.jpg "<div>How I'm Talking to Clients About Retirement Planning for Single Women</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1130632553-38822bfdc2a04e538c6c7e044ab1d699.jpg "Timeshares: Dream Vacation or Money Pit?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1230419950-e22af8167a5843d7b42b95d521f45492.jpg "How Black Inventors Contributed to Industrialization")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1441453430-48795dfcf1724233a8137dca718d3b03.jpg "<div>Gross Profit Margin vs. Net Profit Margin: What's the Difference?</div>")